Literature DB >> 17361927

[Non-operative management of blunt abdominal injuries].

Cristina Marmorale1, Gianluca Guercioni, Walter Siquini, Salem Asselhab, Pierpaolo Stortoni, Maurizio Fianchini, Aroldo Fianchini, Eduardo Landi.   

Abstract

Over the past three decades, non-operative management has been shown to be an effective therapeutic option in hemodynamically stable patients. We retrospectively reviewed the last 7 years of our experience with the non-operative management of blunt abdominal traumas. From January 1998 to July 2005, 123 patients with blunt abdominal traumas and injuries to the spleen, liver and pancreas were admitted to our hospital. Fifty-eight of them (47.2%) were submitted to non-operative management; 5 (8.6%) presented associated splenic and hepatic injuries. We performed non-operative treatment for 27 splenic injuries (33.7% of all splenic injuries), 32 hepatic injuries (62.7% of all hepatic injuries) and 3 pancreatic injuries (75% of all pancreatic injuries). There was no mortality and no complications. We submitted one haemodynamically stable patient who presented a grade V hepatic injury and "contrast pooling" at abdominal CT scan to angiography and transarterial embolisation; this patient was successfully managed non-operatively. The overall success rate of non-operative management was 98.5%. The only non-operative management failure was a patient with both splenic and hepatic injuries. The success rate for injuries to the spleen was 96.3%, to the liver 96.9% and to the pancreas 100%. We conclude that hemodynamically stable patients suffering intra-abdominal injury can be safely managed non-operatively.

Entities:  

Mesh:

Year:  2007        PMID: 17361927

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  1 in total

1.  Non operative management of abdominal trauma - a 10 years review.

Authors:  Mohsin Raza; Yasser Abbas; Vanitha Devi; Kumarapuram Venkatachalam Souriarajan Prasad; Kameel Narouz Rizk; Permasavaran Padmanathan Nair
Journal:  World J Emerg Surg       Date:  2013-04-05       Impact factor: 5.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.